Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Pilla

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
The Lancet. Oncology|June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyJean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptidesPaola Filipazzi, Lorenzo Pilla, Luigi Mariani, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO studyElisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findingsFiliberto Belli, Alessandro Testori, Licia Rivoltini, et al.
International Journal of Cancer|November 16, 2012
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytesVincenzo Russo, Lorenzo Pilla, Francesca Lunghi, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
The Lancet. Oncology|June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyJean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptidesPaola Filipazzi, Lorenzo Pilla, Luigi Mariani, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO studyElisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findingsFiliberto Belli, Alessandro Testori, Licia Rivoltini, et al.
International Journal of Cancer|November 16, 2012
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytesVincenzo Russo, Lorenzo Pilla, Francesca Lunghi, et al.
Pageof 4